Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference. Together, they explore the latest data on Retatrutide's potential to deliver bariatric surgery-level weight loss, improve cardiometabolic health, and reshape the future of obesity and type 2 diabetes treatment.otplinks.com
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from On The Pen GLP-1 News
What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs
Retatrutide Before FDA Approval? Lilly Just Changed the Conversation
Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs
Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War
Get summaries like this every morning.
Free AI-powered recaps of On The Pen GLP-1 News and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.